NANOG and glioma: Current studies have reported that the expression of Nanog was higher in multiple cancerous tissues than in their normal counterparts, including breast cancer [20], gastric adenocarcinomas [21], colorectal cancer [22], gliomas [23] and ovarian serous cystadenocarcinomas [24].